Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesFirefly Neuroscience, Inc.

Firefly Neuroscience, Inc.

Technology Software - Application
PortfolioPortfolio WatchlistWatchlist
Company price
1.04 USD 0.06 ( 6.12%)
Last update at 2026-11-11T21:00:00Z
VOLUME
63067
Market Cap
15.69M

Momentum Score

…

Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury. It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.99
Low
1.05
High
52 Week Price Range
0.62
Low
3.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Firefly Neuroscience develops portable, non‑invasive brain monitoring systems and digital biomarkers intended to measure neural function for neurological disorders and clinical research. Growth drivers may include demand for objective biomarkers, adoption by clinical trials and research organizations, and population aging increasing focus on neurodegenerative disease, making the company potentially attractive to investors seeking exposure to scalable neurodiagnostic tools.
Principal risks include limited public clinical validation and regulatory clearance for its biomarkers, intense competition from established EEG and neurotechnology firms, and execution and financing risk associated with early‑stage medical device companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.98
Dividend Yield
-
Revenue TTM
1.80M
Revenue Per Share
0.12
Gross Profit TTM
0.80M
Debt / Equity
-1.85
ROE
-68.06%
Net Debt
-2.75M
ROCE
-257.48%
Diluted EPS TTM
-0.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -19.88M -10.46M -2.60M -3.79M -4.38M
Net income -19.88M -10.46M -2.60M -3.79M -4.38M
Selling general administrative 6.97M 6.13M 2.20M 1.98M 1.68M
Selling and marketing expenses 0.80M 1.20M 0.64M - -
Gross profit 0.65M 0.04M 0.50M 0.00M 0.03M
Reconciled depreciation 0.17M 0.07M 0.00M 0.01M 0.43M
Ebit -19.72M -10.39M -3.08M - -
Ebitda -19.55M -10.32M -2.58M - -
Depreciation and amortization 0.17M 0.07M - - -
Operating income -8.61M -9.18M -3.08M -3.25M -4.62M
Other operating expenses 9.75M 9.29M 3.58M - -
Interest expense 0.16M 0.07M 0.02M 0.57M 0.14M
Tax provision 0.01M 0.00M 0.00M 0.00M 0.00M
Interest income 0.09M 0.00M - - -
Net interest income -0.07M -0.07M -0.02M -0.57M -0.14M
Income tax expense 0.01M 0.00M 0.00M - -
Total revenue 1.14M 0.11M 0.50M 0.00M 0.03M
Total operating expenses 9.25M 9.22M 3.58M 3.25M 4.65M
Cost of revenue 0.50M 0.07M - 0.00M 0.00M
Total other income expense net -11.27M -1.28M 0.48M 0.04M 0.37M
Net income from continuing ops -19.88M -10.46M -2.60M -3.79M -4.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10.48M 4.60M 2.64M 0.14M 0.95M
Intangible assets 0.86M 0.18M 0.39M - -
Other current assets 0.98M 0.70M 0.03M - -
Total liab 2.84M 4.98M 2.53M 2.25M 3.97M
Total stockholder equity 7.64M -0.38M 0.11M -2.11M -3.01M
Other current liab 1.24M 2.45M 1.90M - -
Common stock 0.00M - - - -
Capital stock 0.00M 0.00M 0.00M 0.02M 2.43M
Retained earnings -111.61M -87.08M -76.62M -73.91M -67.33M
Good will 5.17M 0.00M - - -
Cash 2.75M 1.81M 2.14M 0.06M 0.65M
Total current liabilities 2.82M 4.98M 2.53M 2.25M 3.97M
Current deferred revenue 0.23M 0.01M - - -
Net debt -2.75M -1.12M -2.14M - 1.14M
Short term debt - 0.69M - - -
Short long term debt - 0.69M - - 1.79M
Short long term debt total - 0.69M - - -
Other stockholder equity 119.25M 86.71M 76.73M - -
Total current assets 4.03M 2.63M 2.25M 0.08M 0.70M
Net receivables 0.19M 0.12M 0.08M - -
Inventory 0.11M 0.00M - - -
Accounts payable 1.35M 1.82M 0.63M 0.42M 0.50M
Non currrent assets other 0.27M 1.66M - - -
Non current assets total 6.45M 1.97M 0.39M 0.05M 0.25M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.48M -0.39M 0.26M 1.60M
Total cashflows from investing activities -2.49M -0.48M -0.39M - -
Net borrowings 2.53M 1.96M 0.00M - -
Total cash from financing activities 11.62M 6.30M 4.64M 2.04M 2.04M
Net income -19.88M -10.46M -2.60M -3.79M -4.38M
Change in cash 0.94M -0.33M 2.08M -0.59M -0.18M
Begin period cash flow 1.81M 2.14M 0.06M 0.65M 0.83M
End period cash flow 2.75M 1.81M 2.14M 0.06M 0.65M
Total cash from operating activities -8.19M -6.16M -2.17M -2.89M -3.82M
Issuance of capital stock 0.00M 4.31M 4.64M 0.29M 0.00M
Depreciation 0.17M 0.07M 0.00M 0.01M 0.43M
Other cashflows from investing activities - -0.33M - - -
Change to inventory -0.04M 0.00M - - -
Change to account receivables -0.03M -0.04M -0.07M - -
Other cashflows from financing activities - 0.04M - - -
Capital expenditures 0.13M 0.41M 0.39M 0.00M 0.00M
Change in working capital -1.18M 0.45M 0.14M 0.39M -0.19M
Stock based compensation 0.78M 2.72M 0.29M 0.06M 0.61M
Other non cash items 11.92M 1.07M - 0.46M 0.13M
Free cash flow -8.32M -6.57M -2.56M -2.89M -3.82M

Peer Comparison*

Sector: Technology Industry: Software - Application

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
AIFF
Firefly Neuroscience, Inc.		 0.06
6.12%		 1.04 - - 8.72 1.13 8.62
SAP
SAP SE ADR		 0.36
0.15%		 234.10 28.16 22.42 6.52 4.85 5.60
CRM
Salesforce Inc		 4.02
1.88%		 217.50 23.41 15.55 4.79 5.56 5.55
SAPGF
SAP SE		 -0.33
0.14%		 234.00 76.28 22.88 5.61 3.84 5.59
SHOP
Shopify Inc		 2.65
1.81%		 149.26 90.18 53.19 12.70 13.17 12.23

Profile*

Firefly Neuroscience, Inc.

Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury. It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.

1100 Military Road, Kenmore, NY, United States, 14217

888 237 6412

https://fireflyneuro.com

17

Name Title Year Born
Mr. Jon Olsen CEO & Director 1965
Mr. Gil Issachar Chief Technology Officer 1982
Mr. David Ian Johnson Executive Chairman 1958
Dr. Jason DuBraski Vice President of Sales NA
Dr. Samer E. Kaba M.D. Chief Medical Officer 1962
Mr. Greg Lipschitz CEO & Director 1989
Mr. David DeCaprio President, COO & Director 1973
Mr. Gil Issachar Chief Technology Officer 1983
Mr. Paul Krzywicki CPA, CGA CFO & Company Secretary 1985
Mr. Gil Issachar Head of AI & Neuroscience 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…